BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Lung cancer AND MUC16, CA125, CA-125 AND Diagnosis
184 results:

  • 1. Factors influencing blood tumor marker concentrations in the absence of neoplasia.
    Trapé J; Fernández-Galán E; Auge JM; Carbonell-Prat M; Filella X; Miró-Cañís S; González-Fernández C;
    Tumour Biol; 2024; 46(s1):S35-S63. PubMed ID: 38517826
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Humoral immune response to tumor-associated antigen Ubiquilin 1 (UBQLN1) and its tumor-promoting potential in lung cancer.
    Wang Y; Ouyang S; Liu M; Si Q; Zhang X; Zhang X; Li J; Wang P; Ye H; Shi J; Song C; Wang K; Dai L
    BMC Cancer; 2024 Mar; 24(1):283. PubMed ID: 38431566
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Diagnostic value of cerebrospinal fluid human epididymis protein 4 for leptomeningeal metastasis in lung adenocarcinoma.
    Li X; Chen K; Li J; Tang X; Ruan H; Guan M
    Front Immunol; 2024; 15():1339914. PubMed ID: 38304432
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Improvement of differential diagnosis of lung cancer by use of multiple protein tumor marker combinations.
    Trulson I; Klawonn F; von Pawel J; Holdenrieder S
    Tumour Biol; 2024; 46(s1):S81-S98. PubMed ID: 38277317
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. IR808@MnO nano-near infrared fluorescent dye's diagnostic value for malignant pleural effusion.
    Wang X; Yan X; Zhang Z; Xu C; Du F; Xie Y; Yin X; Lei Z; Jiang Y; Yang W; Zhou X; Wang Y
    Respir Res; 2024 Jan; 25(1):22. PubMed ID: 38195540
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Integrative Multianalytical Model Based on Novel Plasma Protein Biomarkers for Distinguishing lung Adenocarcinoma and Benign Pulmonary Nodules.
    Zhang X; Ji L; Liu M; Li J; Sun H; Liang F; Zhao Y; Wang Z; Yang T; Wang Y; Si Q; Du R; Dai L; Ouyang S
    J Proteome Res; 2024 Jan; 23(1):277-288. PubMed ID: 38085828
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. [Diagnostic values of conventional tumor markers and their combination with chest CT for patients with stageⅠA lung cancer].
    Peng Q; Wu N; Huang Y; Zhao SJ; Tang W; Liang M; Ran YL; Xiao T; Yang L; Liang X
    Zhonghua Zhong Liu Za Zhi; 2023 Nov; 45(11):934-941. PubMed ID: 37968078
    [No Abstract]    [Full Text] [Related]  

  • 8. The blood proteome of imminent lung cancer diagnosis.
    Lung Cancer Cohort Consortium (LC3)
    Nat Commun; 2023 Jun; 14(1):3042. PubMed ID: 37264016
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. [Cytopathological characterization of ascites for the diagnosis of serous ovarian carcinoma].
    Chang YH; Zou BQ; Cai Y; Yang SD; Zhang Y; Liang JB; Li C
    Zhonghua Zhong Liu Za Zhi; 2023 May; 45(5):424-432. PubMed ID: 37188628
    [No Abstract]    [Full Text] [Related]  

  • 10. Clinical role of serum tumor markers SCC, NSE, CA 125, CA 19-9, and CYFRA 21-1 in patients with lung cancer.
    Sun A
    Lab Med; 2023 Nov; 54(6):638-645. PubMed ID: 37052517
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Genetic analysis of familial predisposition in the pathogenesis of malignant pleural mesothelioma.
    Akarsu M; Ak G; Dündar E; Metintaş M
    J Cancer Res Clin Oncol; 2023 Aug; 149(10):7767-7778. PubMed ID: 37027032
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. A case of malignant peritoneal mesothelioma with a Fitz-Hugh-Curtis syndrome-like imaging finding.
    Iwadare T; Kimura T; Nagata Y; Suzuki H; Kunimoto H; Kitabatake H; Seki A; Ochi Y; Hara E; Umemura T
    Clin J Gastroenterol; 2023 Jun; 16(3):372-376. PubMed ID: 36781827
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Liquid biopsy-based decision support algorithms for diagnosis and subtyping of lung cancer.
    Visser E; Genet SAAM; de Kock RPPA; van den Borne BEEM; Youssef-El Soud M; Belderbos HNA; Stege G; de Saegher MEA; van 't Westeinde SC; Brunsveld L; Broeren MAC; van de Kerkhof D; Deiman BALM; Eduati F; Scharnhorst V
    Lung Cancer; 2023 Apr; 178():28-36. PubMed ID: 36773458
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Combination of serum ACSL4 levels and low-dose 256-slice spiral CT exhibits the potential in the early screening of lung cancer.
    Yu W; Wang L; Liu S; Liu Y; Wang S; Sun X
    Medicine (Baltimore); 2023 Feb; 102(5):e32733. PubMed ID: 36749237
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Increased levels of N6-methyladenosine in peripheral blood RNA: a perspective diagnostic biomarker and therapeutic target for non-small cell lung cancer.
    Yin H; Hong H; Yin P; Lu W; Niu S; Chen X; Xia Y; Jiang P; Huang Z
    Clin Chem Lab Med; 2023 Feb; 61(3):473-484. PubMed ID: 36542027
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. A case report of anterior mediastinal signet ring cell carcinoma.
    Liu S; Zhao A; Mao M
    Medicine (Baltimore); 2022 Dec; 101(48):e32202. PubMed ID: 36482538
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Serum Markers ca125, CA153, and CEA along with Inflammatory Cytokines in the Early Detection of lung cancer in High-Risk Populations.
    Li G; Zhang H; Zhang L; Liu H; Li S; Wang Y; Deng X
    Biomed Res Int; 2022; 2022():1394042. PubMed ID: 36299704
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Combined measurement of circulating tumor cell counts and serum tumor marker levels enhances the screening efficiency for malignant versus benign pulmonary nodules.
    Ma G; Yang D; Li Y; Li M; Li J; Fu J; Peng Z
    Thorac Cancer; 2022 Dec; 13(23):3393-3401. PubMed ID: 36284506
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. [muc16: The Novel Target for Tumor Therapy].
    Gao R; Lou N; Han X; Shi Y
    Zhongguo Fei Ai Za Zhi; 2022 Jul; 25(7):452-459. PubMed ID: 35899441
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Multivariate Analysis on Development of lung Adenocarcinoma Lesion from Solitary Pulmonary Nodule.
    Yu L; Zhang B; Zou H; Shi Y; Cheng L; Zhang Y; Zhen H
    Contrast Media Mol Imaging; 2022; 2022():8330111. PubMed ID: 35795880
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 10.